Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.

ABSTRACT:

Background

Widespread adoption of genomic technologies in the management of heterogeneous indications, including Multiple Myeloma, has been hindered by concern over variation between published gene expression signatures, difficulty in physician interpretation and the challenge of obtaining sufficient genetic material from limited patient specimens.

Methods

Since 2006, the 70-gene prognostic signature, developed by the University of Arkansas for Medical Sciences (UAMS) has been applied to over 4,700 patients in studies performed in 4 countries and described in 17 peer-reviewed publications. Analysis of control sample and quality control data compiled over a 12-month period was performed.

Results

Over a 12 month period, the 70-gene prognosis score (range 0-100) of our m

SUBMITTER: van Laar R 

PROVIDER: S-EPMC4032347 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature